iRGD-modified exosomes-delivered BCL6 siRNA inhibit the progression of diffuse large B-cell lymphoma

iRGD-modified exosomes-delivered BCL6 siRNA inhibit the progression of diffuse large B-cell lymphoma

Clinical applications of siRNA therapeutics have been limited by the immunogenicity of the siRNA and low efficiency of siRNA delivery to target cells. Recently, evidence have shown that exosomes, endogenous nano-vesicles, can deliver siRNA to the tumor tissues in mice. Here, to reduce immunogenicity...

Full description

Bibliographic Details
Main Authors: Qinhua Liu, Guanrong Dai, Yi Wu, Mingxia Zhang, Mingya Yang, Xiaonan Wang, Mingyue Song, Xiaodan Li, Ruixiang Xia, Zhengsheng Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
diffuse large B-cell lymphoma
small interfering RNA
exosomes
BCL6
delivery vehicle
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.822805/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.822805/full

Similar Items